NeuroSense Therapeutics reported financial results for H1 2024, with a net loss of $6.26 million compared to $6.57 million in H1 2023. Research and development expenses decreased 9.4% to $3.45 million, while general and administrative expenses remained stable at $2.57 million. As of June 30, 2024, the company had cash of $1.20 million.The company's lead candidate PrimeC showed positive 12-month data from the PARADIGM clinical trial in ALS treatment, demonstrating significant improvement in disease progression and survival rates. NeuroSense plans to meet with FDA and EMA in Q4 2024 and commence a pivotal trial in H1 2025.To strengthen its financial position, NeuroSense raised additional capital through multiple offerings in 2024, including a $4.5 million registered direct offering in June and a $0.6 million private placement in August. The company also established a $2.52 million equity program with JonesTrading, under which it has raised $276,000 to date through share sales.

NeuroSense Therapeutics reported financial results for H1 2024, with a net loss of $6.26 million compared to $6.57 million in H1 2023. Research and development expenses decreased 9.4% to $3.45 million, while general and administrative expenses remained stable at $2.57 million. As of June 30, 2024, the company had cash of $1.20 million.The company's lead candidate PrimeC showed positive 12-month data from the PARADIGM clinical trial in ALS treatment, demonstrating significant improvement in disease progression and survival rates. NeuroSense plans to meet with FDA and EMA in Q4 2024 and commence a pivotal trial in H1 2025.To strengthen its financial position, NeuroSense raised additional capital through multiple offerings in 2024, including a $4.5 million registered direct offering in June and a $0.6 million private placement in August. The company also established a $2.52 million equity program with JonesTrading, under which it has raised $276,000 to date through share sales.